USPTO serial 78150365
THE LUMINEX LABORATORY
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- CLARKE, NANCY
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with THE LUMINEX LABORATORY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Pamela S. Ratliff
PAMELA S RATLIFF BAKER BOTTS LLP2001 ROSS AVE STE 600DALLAS, TX 75230UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Diagnostic reagents and microspheres for scientific or research use for conducting molecular analysis using flow microfluorimetry and/or multiemission ratiometric fluorophors for healthcare, environmental, agricultural, diagnostic, and other applications | ACTIVE | — |
| 005 | Diagnostic reagents and microspheres for clinical or medical use for conducting molecular analysis using flow microfluorimetry and/or multiemission ratiometric fluorophors for healthcare, environmental, agricultural, diagnostic, and other applications | ACTIVE | — |
| 009 | Computer software containing databases of information in the field of bioinformatics; database management and searching software for use in the field of bioinformatics; series of algorithms that generate decision rules and computer programs that apply decision rules to data | ACTIVE | — |
| 042 | Drug discovery services; pharmaceutical research services; pre-clinical screening, and clinical trial, research and evaluation services; bioinformatics, biosignatures, genomics, proteomics and pharmacology research services; development of human disease models for use in evaluation of drugs and discovery of new drugs; drug discovery, drug screening, pre-clinical and pharmaceutical programs; research and development of new diagnostic products and services for others; compilation of databases for use in pharmaceutical research; compilation of databases for use in research into human gene and human protein functions; design of computer models for use in pre-clinical, clinical and pharmaceutical research; consultancy, information and advisory services for all the aforesaid services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Luminex Corporation
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Similar marks named THE LUMINEX LABORATORY
- Prosecution event ABN2 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 20, 2003 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Dec 30, 2002 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 23, 2002 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 6, 2002 | PAPER RECEIVED | — |